A new therapeutic target turns the immune system against lymphoma
(Ecole Polytechnique F é d é rale de Lausanne) EPFL scientists have identified a key mechanism that tumor cells use to take advantage of and avoid detection from the immune system. Targeting this mechanism offers a new therapeutic strategy for cancers like Non-Hodgkin lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2020 Category: Cancer & Oncology Source Type: news
NFCR-backed technology receives FDA's assent for lymphoma clinical trials
(National Foundation for Cancer Research) National Foundation for Cancer Research-backed drug and drug delivery technology receives assent from US Food and Drug Administration for T-cell non-Hodgkin's lymphoma clinical trials. The milestone represents another example of promising translational cancer research supported by the organization and its donors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2020 Category: Cancer & Oncology Source Type: news
Caution: Higher Radiation Dose Linked to Worse NHL Outcomes Caution: Higher Radiation Dose Linked to Worse NHL Outcomes
Among patients with non-Hodgkin lymphoma who underwent reduced-intensity conditioning for stem cell transplant, overall survival was lower if they received a higher dose of radiation.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 21, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
A randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared...
The objective of this study was to compare the safety and antitumor activity of F14512 and etoposide phosphate in dogs with spontaneous non-Hodgkin lymphoma and to investigate the potential benefit of F14512 in P-glycoprotein overexpressing lymphomas. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2020 Category: International Medicine & Public Health Source Type: news
Young Cancer Survivors at Higher Risk for Hospitalization
Risks most elevated for survivors of leukemia, CNS tumors, CRC, non - Hodgkin lymphoma, breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 12, 2020 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Oncology, Pediatrics, Journal, Source Type: news
Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma
Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease. (Source: CancerNetwork)
Source: CancerNetwork - February 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma
(University of Texas M. D. Anderson Cancer Center) According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2020 Category: Cancer & Oncology Source Type: news
FDA clears investigational new drug application for Calibr's 'switchable' CAR-T therapy
(Scripps Research Institute) Calibr, the drug discovery and development division of Scripps Research, today announced that the US Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's 'switchable' CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 3, 2020 Category: International Medicine & Public Health Source Type: news
Nitrite Consumption May Up Risk for Non-Hodgkin Lymphoma
THURSDAY, Jan. 30, 2020 -- Nitrite consumption is associated with an increased risk for non-Hodgkin lymphoma (NHL), according to a meta-analysis published online Jan. 17 in Scientific Reports.
Mengxia Yu, from Zhejiang University in Hangzhou, China,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 30, 2020 Category: Pharmaceuticals Source Type: news
Georgia Sterilization Plant Hit with Hefty Fines for EtO Violation
An Atlanta, GA-based medical sterilization plant is learning an expensive lesson after missing a critical deadline related to ethylene oxide (EtO) pollution controls.
Sterilization Services of Georgia received a permit on Nov. 7 to use EtO to sterilize medical devices, but the company was supposed to install filters to reduce the gas by Dec. 31. The filters were fully operational as of Jan. 18, according to a Jan. 20 letter, but the Georgia Environmental Protection Department (EPD) fined the company $3,000 for each day beyond the deadline that the filters were not connected. In the letter to the Geo...
Source: MDDI - January 29, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Sterilization Source Type: news
Hashimoto Thyroiditis in Primary Thyroid Non-Hodgkin Lymphoma Hashimoto Thyroiditis in Primary Thyroid Non-Hodgkin Lymphoma
How prevalent is Hashimoto thyroiditis in cases of primary thyroid lymphoma, and what is its etiology? Is Hashimoto thryoiditis a necessary condition for the development of PTL?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 21, 2020 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Report: Roundup cases climb as Bayer edges closer to settlement
The mediator appointed to resolve lawsuits filed against Monsanto Co. involving its Roundup weedkiller said Bayer AG may be weeks away from settling claims that have ballooned to more than 75,000.
The plaintiffs in the cases contend that their use of Roundup caused them to develop non-Hodgkin's lymphoma.
In an interview with Bloomberg Thursday, Ken Feinberg reiterated his sentiment that he's “cautiously optimistic” about reaching a deal within a month. But he said the caseload — whic h Bayer,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 17, 2020 Category: Biotechnology Authors: Erik Siemers Source Type: news
Using HDAC3 Inhibitors to Reverse CREBBP Mutations in Lymphomas
This research could potentially pave the way for possible immunotherapy approaches for common forms of non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - January 13, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
The Big Number: Why your risks for 7 types of cancer could be reduced with physical activity
Research shows several exercises can be effective against these cancers: breast, colon, endometrial, kidney, liver, multiple myeloma and non-Hodgkin lymphoma. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - January 12, 2020 Category: Consumer Health News Authors: Linda Searing Source Type: news
Exercise may reduce risk for cancer by as much as 25 percent
People who engaged in physical activity as recommended by the NIH were able to reduce their risk for colon and breast cancers, as well as endometrial cancer, kidney cancer, myeloma, liver cancer and non-Hodgkin lymphoma. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 26, 2019 Category: Consumer Health News Source Type: news
